When Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies, several of its competitors saw their stocks rise – including Biogen and Eisai.
https://www.pharmalive.com/wp-content/uploads/2021/12/Roches-Latest-Checkpoint-Target-Shows-Promise-for-Lung-Cancer-BioSpace-12-10-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-16 08:50:242022-11-16 09:12:02Roche failure leaves industry reassessing Alzheimer’s space
